OBJECTIVE: We previously showed that Adamantiades-Behçet's disease (A-BD) is associated with a lower incidence of malignancy compared with the general population. Transforming growth factor-beta (TGF-beta) has been shown to play a role in cartilage regeneration and is increased in patients with A-BD. We also found 2 functional polymorphisms of the TGF-beta pathway, TGFBR1*6A and TGFB1*CC, that are associated with risk of malignancy. We tested whether incidence of these polymorphisms would differ in patients with A-BD compared with healthy controls of similar age and geographic location. METHODS: We performed a case-control study including 139 cases and 128 controls from Greece. Cases and controls were genotyped for TGFBR1*6A and TGFB1*CC. RESULTS: We found that cases had lower incidence of TGFBR1*6A compared with controls (11.3% vs 13.3%, respectively). Also, the incidence of TGFB1*CC was lower in cases than controls (24.6% vs 27.0%, respectively). These differences were not statistically significant. CONCLUSION: Although there is a suggestion that the lower incidence of TGFBR1*6A in A-BD patients may play a protective role against development of malignancy, larger studies would be needed to fully evaluate the role of TGF-beta and its polymorphisms in A-BD.
OBJECTIVE: We previously showed that Adamantiades-Behçet's disease (A-BD) is associated with a lower incidence of malignancy compared with the general population. Transforming growth factor-beta (TGF-beta) has been shown to play a role in cartilage regeneration and is increased in patients with A-BD. We also found 2 functional polymorphisms of the TGF-beta pathway, TGFBR1*6A and TGFB1*CC, that are associated with risk of malignancy. We tested whether incidence of these polymorphisms would differ in patients with A-BD compared with healthy controls of similar age and geographic location. METHODS: We performed a case-control study including 139 cases and 128 controls from Greece. Cases and controls were genotyped for TGFBR1*6A and TGFB1*CC. RESULTS: We found that cases had lower incidence of TGFBR1*6A compared with controls (11.3% vs 13.3%, respectively). Also, the incidence of TGFB1*CC was lower in cases than controls (24.6% vs 27.0%, respectively). These differences were not statistically significant. CONCLUSION: Although there is a suggestion that the lower incidence of TGFBR1*6A in A-BD patients may play a protective role against development of malignancy, larger studies would be needed to fully evaluate the role of TGF-beta and its polymorphisms in A-BD.
Authors: P P Sfikakis; N Markomichelakis; E Alpsoy; S Assaad-Khalil; B Bodaghi; A Gul; S Ohno; N Pipitone; M Schirmer; M Stanford; B Wechsler; C Zouboulis; P Kaklamanis; H Yazici Journal: Rheumatology (Oxford) Date: 2007-04-02 Impact factor: 7.580
Authors: I Ertenli; S Kiraz; M Calgüneri; I Celik; M Erman; I C Haznedaroglu; S Kirazli Journal: Clin Exp Rheumatol Date: 2001 Sep-Oct Impact factor: 4.473
Authors: Virginia G Kaklamani; Nanjiang Hou; Yiansong Bian; Jennifer Reich; Kenneth Offit; Loren S Michel; W S Rubinstein; Alfred Rademaker; Boris Pasche Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544
Authors: Alison M Dunning; Peter D Ellis; Simon McBride; Heidi L Kirschenlohr; Catherine S Healey; Paul R Kemp; Robert N Luben; Jenny Chang-Claude; Arto Mannermaa; Vesa Kataja; Paul D P Pharoah; Douglas F Easton; Bruce A J Ponder; James C Metcalfe Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: B Pasche; Y Luo; P H Rao; S D Nimer; E Dmitrovsky; P Caron; L Luzzatto; K Offit; C Cordon-Cardo; B Renault; J M Satagopan; V V Murty; J Massagué Journal: Cancer Res Date: 1998-07-01 Impact factor: 12.701
Authors: Elaine F Remmers; Fulya Cosan; Yohei Kirino; Michael J Ombrello; Neslihan Abaci; Colleen Satorius; Julie M Le; Barbara Yang; Benjamin D Korman; Aris Cakiris; Oznur Aglar; Zeliha Emrence; Hulya Azakli; Duran Ustek; Ilknur Tugal-Tutkun; Gulsen Akman-Demir; Wei Chen; Christopher I Amos; Michael B Dizon; Afet Akdag Kose; Gulsevim Azizlerli; Burak Erer; Oliver J Brand; Virginia G Kaklamani; Phaedon Kaklamanis; Eldad Ben-Chetrit; Miles Stanford; Farida Fortune; Marwen Ghabra; William E R Ollier; Young-Hun Cho; Dongsik Bang; John O'Shea; Graham R Wallace; Massimo Gadina; Daniel L Kastner; Ahmet Gül Journal: Nat Genet Date: 2010-07-11 Impact factor: 38.330